
Bristol-Myers Squibb Co.
BMYBristol-Myers Squibb Co. is a global pharmaceutical company focused on discovering, developing, and delivering innovative medicines in areas such as oncology, immunology, cardiovascular, and neuroscience. Founded in 1858, it has a long history of advancing health through its diverse portfolio of prescription therapies.
Dividend History
Investors can expect a dividend payout of $0.63 per share, scheduled to be distributed in 27 days on February 2, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 2, 2026 | $0.63 | 2026-01-02 | 2026-01-02 |
| November 3, 2025 | $0.62 | 2025-10-03 | 2025-10-03 |
| August 1, 2025 | $0.62 | 2025-07-03 | 2025-07-03 |
| May 1, 2025 | $0.62 | 2025-04-04 | 2025-04-04 |
| February 3, 2025 | $0.62 | 2025-01-03 | 2025-01-03 |
Dividends Summary
- Bristol-Myers Squibb Co. has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 64 days ago, on November 3, 2025
- The highest dividend payed out to investors during this period was $0.63 per share
- The average dividend paid during this period was $0.40 per share.
Company News
Matt DiLallo recommends loading up on the Schwab U.S. Dividend Equity ETF (SCHD) in 2026. The ETF tracks the top 100 high-yielding dividend stocks with strong dividend growth histories. After underperforming in 2025 (up only 1% vs S&P 500's 17%), SCHD now trades at a more attractive valuation (17x earnings vs S&P 500's 25x) with a 3.7% dividend y...
The global immuno-oncology clinical trials market is expected to grow from USD 8.30 billion in 2023 to USD 23.63 billion by 2032, driven by rising cancer incidence, significant R&D investments, and advancements in immunotherapies like checkpoint inhibitors and CAR-T cell therapies.
BioNTech and Bristol Myers Squibb reported promising interim data for pumitamig, a drug combination showing encouraging anti-tumor responses for triple-negative breast cancer patients with limited treatment options.
The article highlights four high-yielding dividend stocks trading at attractive valuations amid market uncertainty, focusing on packaging and pharmaceutical companies with strong dividend histories and low valuation metrics.
The healthcare sector has gained momentum recently, with investors rushing to buy beaten-down stocks. The performance of major healthcare ETFs like XLV, VHT, IYH, and FHLC will depend on the upcoming earnings releases of big names like Pfizer, Merck, Amgen, AbbVie, Bristol Myers Squibb, and Eli Lilly.









